PMV Pharmaceuticals: Key Catalysts Approach in Q1 2026
PMV Pharmaceuticals is entering a crucial first quarter of 2026 with several key events for its lead cancer therapy, rezatapopt. Investors are focused on upcoming financial results, a presentation at the TD Cowen Health Care Conference, and the critical completion of patient enrollment for its platinum-resistant ovarian cancer study. Meeting the enrollment target by late March 2026 is essential for the company's planned New Drug Application submission by Q1 2027.
OCT 24·Benzinga▲
PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation - PMV Pharma ( NASDAQ:PMVP )
Data presented today as an oral presentation at 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Confirmed responses observed in eight tumor types spanning ovarian, lung, breast, endometrial, head and neck, colorectal, gallbladder, and ampullary carcinoma
OCT 24·GlobeNewswire→
PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation
PRINCETON, N.J., Oct. 24, 2025 ( GLOBE NEWSWIRE ) -- PMV Pharmaceuticals, Inc. ( "PMV Pharma" or the "Company". Nasdaq: PMVP ) , a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced updated data from the ...
